{
  "docId": "019de077-7395-77e8-a759-85ee5ceb6441",
  "docSlug": "d10c7e5183f0665a04c27575aa737d7a",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 42,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "appendix_data",
  "function": "appendix",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses icons to represent different medical conditions and color-coding for therapeutic areas (Oncology, BioPharma, Rare Disease).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-7395-77e8-a759-85ee5ceb6441/31",
  "deckHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441",
  "deckJsonHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441.json",
  "deckAnchorHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.029,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Multiple blockbuster opportunities with combined peak year revenue >$5bn",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac62f197-7c5e-4f09-8a91-73617ebe1e09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "list",
      "text": "LAURA | Stg III u/r NSCLC; ECHO | MCL; AMPLIFY | CLL; DESTINY-Breast06 | mBC; CAPItello-281 | dPTEN mHSPC; ADRIATIC | LS-SCLC; NIAGARA | MIBC; WAYPOINT | CRSwNP; KOMET | adult NF1-PN",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08c7fb59-1717-41fc-bdf0-8756c3fef8e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.68,
        "x": 0.048,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Total non-risk adjusted Peak Year Revenue estimate for the 9 trials shown on this slide. Collaboration partners: Daiichi Sankyo (Enhertu); Amgen (Tezspire); Merck & Co., Inc. (Koselugo). Appendix: Glossary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7841f4a4-c99c-4654-a7f3-ddeed586d2cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.51,
        "x": 0.048,
        "y": 0.056
      },
      "kind": "title",
      "text": "Appendix – 9 high-value positive Phase III trials in 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22e29e16-1b21-4978-bf1e-d50f62bf0cb5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "41c19469-691c-4244-874c-57b47bdd1fd7",
      "evidence": "The slide contains a list/bullet component with several items.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}